Unmet needs in regulatory science for generic drugs

TL;DR

Generic drugs have seen a significant increase in usage, but there is a need for continued research and regulatory science to ensure their therapeutic equivalence and address challenges with complex products.

Transcript

Stanford University thank you very thank you very much it's a pleasure a pleasure to be here today so today I'm gonna give you an overview of what some of the unmet regulatory science needs in generic drugs are but I want to start with the most important slide I can find to show you what's changed in the past twelve years about generic drugs when I... Read More

Key Insights

• 🥺 The increase in generic drug usage has led to the need for continued research and regulatory science to ensure therapeutic equivalence.
• 😒 FDA's review process for generic drugs focuses on bioequivalence and pharmaceutical equivalence, with an emphasis on bridging studies to support the use of safety and efficacy data from brand products.
• 🥺 The GDUFA has provided FDA with additional resources for regulatory science, leading to the establishment of the Office of Research and Standards and the Division of Therapeutic Performance and Quantitative Methods and Modeling.
• 👍 FDA is conducting post-market evaluation studies to monitor the performance of approved generic drugs and ensure they meet expectations.

Questions & Answers

Q: What are the requirements for a generic drug to be approved by the FDA?

To be approved, a generic drug must have the same active ingredient, route of administration, dosage form, strength, labeling, and conditions of use as the brand product. However, differences in inactive ingredients, formulation design, and manufacturing processes are allowed as long as they do not significantly impact therapeutic equivalence.

Q: How does FDA ensure that generic drugs are therapeutically equivalent to brand drugs?

FDA's review process focuses on bioequivalence and pharmaceutical equivalence. This involves conducting in vivo pharmacokinetic studies to compare exposure levels of the generic and brand products, as well as in vitro laboratory testing to assess drug release and formulation consistency.

Q: What are the challenges in evaluating generic drugs for locally acting products?

Locally acting products, such as ophthalmic or nasal formulations, present challenges in determining bioequivalence due to their unique drug delivery mechanisms. FDA is working on developing new modeling and simulation tools and in vitro methods to better evaluate these products.

Q: How does FDA address complex products, such as liposomal formulations?

FDA has developed specific guidance for the evaluation of liposomal products, which require extensive characterization and testing. The agency also collaborates with external partners to improve modeling and simulation tools and in vitro methods for complex products.

Summary & Key Takeaways

• The percentage of prescriptions filled with generic drugs has increased from 54% to around 86% in the past twelve years, leading to changes in the generic drug industry and FDA's review process.

• Generic drugs need to have the same active ingredient, route of administration, dosage form, strength, labeling, and conditions of use as their brand counterparts, but can differ in inactive ingredients, formulation design, and manufacturing processes.

• FDA's review process for generic drugs focuses on bioequivalence and pharmaceutical equivalence to ensure therapeutic equivalence, and is supported by the Generic Drug User Fee Amendments (GDUFA).